BRPI0511367A - uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo - Google Patents

uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo

Info

Publication number
BRPI0511367A
BRPI0511367A BRPI0511367-9A BRPI0511367A BRPI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A
Authority
BR
Brazil
Prior art keywords
composition
vip
active fragment
relates
prophylactic
Prior art date
Application number
BRPI0511367-9A
Other languages
English (en)
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004903188A external-priority patent/AU2004903188A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of BRPI0511367A publication Critical patent/BRPI0511367A/pt
Publication of BRPI0511367B1 publication Critical patent/BRPI0511367B1/pt
Publication of BRPI0511367B8 publication Critical patent/BRPI0511367B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)

Abstract

USO DE UMA COMPOSIçãO, COMPOSIçãO, USO DE VIP E/OU DE UM FRAGMENTO ATIVO DO MESMO". A presente invenção está relacionada com composição e métodos para tratamento de determinadas condições cardiovasculares. Em particular, ela está relacionada com o tratamento profilático ou terapêutico da fibrose miocardial ou condições associadas através da administração de composições compreendendo peptídeo intestinal vasoativo (VIP) e/ou fragmento(s) ativo(s) do mesmo.
BRPI0511367A 2004-06-11 2005-06-10 uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo BRPI0511367B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004903188A AU2004903188A0 (en) 2004-06-11 Treatment of myocardial fibrosis
AU2004903188 2004-06-11
PCT/AU2005/000835 WO2005120545A1 (en) 2004-06-11 2005-06-10 Compositions and methods for treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
BRPI0511367A true BRPI0511367A (pt) 2007-12-04
BRPI0511367B1 BRPI0511367B1 (pt) 2018-05-22
BRPI0511367B8 BRPI0511367B8 (pt) 2021-05-25

Family

ID=35502830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511367A BRPI0511367B8 (pt) 2004-06-11 2005-06-10 uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo

Country Status (16)

Country Link
US (1) US7951777B2 (pt)
EP (1) EP1768689B1 (pt)
JP (1) JP4824682B2 (pt)
KR (2) KR101638308B1 (pt)
CN (1) CN1993137B (pt)
AU (1) AU2005251386B8 (pt)
BR (1) BRPI0511367B8 (pt)
CA (1) CA2573439C (pt)
DK (1) DK1768689T3 (pt)
ES (1) ES2523659T3 (pt)
IL (1) IL179931A (pt)
MX (1) MXPA06014462A (pt)
NZ (1) NZ552130A (pt)
RU (1) RU2387454C2 (pt)
WO (1) WO2005120545A1 (pt)
ZA (1) ZA200700070B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523659T3 (es) * 2004-06-11 2014-11-28 Vectus Biosystems Limited Composiciones y procedimientos para el tratamiento de enfermedades cardiovasculares
WO2006012394A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
NZ623674A (en) 2005-12-09 2014-07-25 Vectus Biosystems Ltd Vip fragments and methods of use
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2187929A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
CA2738549A1 (en) * 2008-09-25 2010-04-01 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
ES2603963T3 (es) * 2008-10-17 2017-03-02 Vectus Biosystems Limited Composiciones y métodos para el tratamiento de trastornos renales
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
NZ595726A (en) * 2009-04-02 2013-06-28 Vectus Biosystems Pty Ltd Compositions and methods for treatment of aortic fibrosis
US9029505B2 (en) * 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CA2779496A1 (en) 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
NO3046901T3 (pt) 2013-09-17 2018-03-17
JP6293266B2 (ja) * 2013-09-17 2018-03-14 ヴェクタス バイオシステムズ リミテッド 高血圧及び／又は線維症の処置用組成物
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN114652817B (zh) 2015-02-09 2026-04-17 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
CN110151973A (zh) * 2019-04-25 2019-08-23 上海交通大学医学院附属瑞金医院 一种生物活性多肽pacap的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880826A (en) * 1971-09-17 1975-04-29 Sami I Said Vasoactive intestinal peptide
US3862927A (en) * 1973-02-26 1975-01-28 Sami I Said Process for preparation of vasoactive intestinal peptide
JPH01501937A (ja) * 1986-11-18 1989-07-06 セネテック・ピーエルシー 腟潤滑誘発方法
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
JPH0840926A (ja) * 1994-08-03 1996-02-13 Yakurigaku Chuo Kenkyusho:Kk 皮膚潰瘍治療薬
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
EP1233811A2 (en) * 1999-11-12 2002-08-28 Leo Rubin Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
AU2072002A (en) 2000-11-28 2002-06-11 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
ES2523659T3 (es) * 2004-06-11 2014-11-28 Vectus Biosystems Limited Composiciones y procedimientos para el tratamiento de enfermedades cardiovasculares
NZ623674A (en) * 2005-12-09 2014-07-25 Vectus Biosystems Ltd Vip fragments and methods of use

Also Published As

Publication number Publication date
CA2573439C (en) 2014-12-09
ES2523659T3 (es) 2014-11-28
JP2008501723A (ja) 2008-01-24
KR20140057411A (ko) 2014-05-12
KR20160017121A (ko) 2016-02-15
AU2005251386B2 (en) 2010-05-13
JP4824682B2 (ja) 2011-11-30
IL179931A (en) 2013-08-29
EP1768689B1 (en) 2014-08-20
BRPI0511367B8 (pt) 2021-05-25
US20080108573A1 (en) 2008-05-08
WO2005120545A1 (en) 2005-12-22
EP1768689A4 (en) 2009-08-12
BRPI0511367B1 (pt) 2018-05-22
DK1768689T3 (en) 2014-12-01
ZA200700070B (en) 2008-05-28
EP1768689A1 (en) 2007-04-04
RU2387454C2 (ru) 2010-04-27
HK1102508A1 (en) 2007-11-23
AU2005251386A1 (en) 2005-12-22
CN1993137A (zh) 2007-07-04
MXPA06014462A (es) 2007-05-23
AU2005251386B8 (en) 2010-10-14
KR101638308B1 (ko) 2016-07-08
US7951777B2 (en) 2011-05-31
CN1993137B (zh) 2015-04-22
CA2573439A1 (en) 2005-12-22
NZ552130A (en) 2009-10-30
RU2007101164A (ru) 2008-07-20
IL179931A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
EA200700684A1 (ru) Полиаминные композиции
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0620566B8 (pt) composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
NO20023473D0 (no) Sammensetninger for levering av en kortisol antagonist
NO20064584L (no) Tetrahydropyridoindolderivater
MY142044A (en) Endoparasiticidal compositions for topical application
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
MY160560A (en) Compositions and methods for treatment of kidney disorders
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
EA200802128A1 (ru) Новые нутрицевтические композиции
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2007134118A3 (en) Protein based composition and methods of using same
CY1119819T1 (el) Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας
SE0401631L (sv) Ny sammansättning
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.